STOCK TITAN

Health Catalyst insider files Form 144 for 2,854-share sale on NASDAQ

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Health Catalyst, Inc. (HCAT) Form 144 notice reports a proposed sale of 2,854 common shares with an aggregate market value of $9,597.15, to be sold through Morgan Stanley Smith Barney LLC on 09/02/2025 on NASDAQ. The shares were acquired on 09/02/2025 as restricted stock from Health Catalyst, Inc. and were granted as compensation. The filer represents they are not aware of undisclosed material adverse information. The filing also discloses a prior sale by Linda Llewelyn of 2,965 restricted shares on 06/02/2025 for gross proceeds of $10,777.18.

Positive

  • Filer provided required Rule 144 details: class, quantity, broker, exchange, acquisition date, and nature of acquisition (compensation).
  • Planned sale routed through a registered broker (Morgan Stanley Smith Barney LLC) and lists NASDAQ as the market.

Negative

  • Insider sold restricted shares recently: 2,965 shares sold on 06/02/2025 for gross proceeds of $10,777.18, which is disclosed in the filing.

Insights

TL;DR Form 144 notifies a planned Rule 144 sale of 2,854 restricted shares acquired as compensation; filing appears procedural and compliant.

The filing documents a proposed sale under Rule 144 through a registered broker, names the broker and exchange, and states acquisition and payment details explicitly: restricted stock acquired and paid as compensation on the same date listed. It includes a recent related sale by the same person in June 2025. From a compliance perspective, the submission contains the core elements required for a Rule 144 notice: class, quantity, acquisition details, sale timing, broker, and a representation about undisclosed material information.

TL;DR Transaction size is modest and routine; filing signals a planned insider disposition via broker on NASDAQ.

The notice shows a small, single-party disposition (2,854 shares, ~$9.6k) to be executed on a specified date via Morgan Stanley Smith Barney. The shares were acquired as restricted compensation on the same date listed and are being sold under Rule 144. A prior sale of 2,965 restricted shares generated ~$10.8k in June 2025. The amounts disclosed are small in absolute terms relative to typical public-company float, suggesting limited market impact; all material transaction details are provided in the form.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 filed for HCAT disclose?

The Form 144 discloses a proposed sale of 2,854 common shares (aggregate market value $9,597.15) to be sold via Morgan Stanley Smith Barney on 09/02/2025 on NASDAQ.

How were the 2,854 HCAT shares acquired?

The filing states the shares were acquired on 09/02/2025 as restricted stock from Health Catalyst, Inc., with the payment characterized as compensation.

Did the filer sell any HCAT shares recently?

Yes. The filing reports a prior sale by Linda Llewelyn of 2,965 restricted shares on 06/02/2025 for gross proceeds of $10,777.18.

Which broker and exchange are involved in the proposed sale?

The proposed sale names Morgan Stanley Smith Barney LLC as the broker and NASDAQ as the exchange.

Does the filer attest to possession of material nonpublic information?

Yes. By signing the notice, the person represents they do not know of any material adverse information about the issuer that has not been publicly disclosed.